Table 1 Baseline characteristics by MDA responder (−R) or non-responder (-NR) status and overall
Measure | MDA-R (N = 157) | MDA-NR (N = 326) | Total (N = 483) | p-value |
|---|---|---|---|---|
Age, mean (SD) | 48.2 (13.7) | 52.1 (10.8) | 50.8 (12.0) | 0.002 |
Female gender, n (%) | 68 (43.3) | 192 (58.9) | 260 (53.8) | 0.001 |
Race, n (%) | 0.121 | |||
White | 143 (91.1) | 307 (94.5) | 450 (93.4) | |
Asian | 8 (5.1) | 13 (4.0) | 21 (4.4) | |
Other | 6 (3.8) | 5 (1.5) | 11 (2.3) | |
Weight kg, mean (SD) | 81.1 (17.3) | 88.1 (21.2) | 85.9 (20.3) | < 0.001 |
BMI kg/m2, mean (SD) | 27.7 (5.1) | 31.0 (7.6) | 30.0 (7.0) | < 0.001 |
Time since PsA onset, mean years (SD) | 10.5 (9.3) | 11.2 (8.9) | 11.0 (9.0) | 0.51 |
Time since PsA diagnosis, mean years (SD) | 7.7 (7.8) | 8.5 (7.8) | 8.2 (7.8) | 0.63 |
CASPAR score, mean (SD) | 4.4 (1.0) | 4.4 (0.9) | 4.4 (0.9) | 0.96 |
Curr. enthesitis, n (%) | 78 (50.0) | 200 (61.7) | 278 (57.9) | 0.017 |
Curr. dactylitis, n (%) | 47 (30.1) | 63 (19.4) | 110 (22.9) | 0.027 |
Curr. psoriasis, n (%) | 149 (94.9) | 304 (93.3) | 453 (93.8) | 0.46 |
PASI total scorea, mean (SD) | 6.3 (6.6) | 6.1 (8.0) | 6.2 (7.5) | 0.77 |
cDMARD at baseline, n (%) | 93 (59.2) | 194 (59.5) | 287 (59.4) | 0.74 |
Methotrexate at baseline, n (%) | 77 (49.0) | 156 (47.9) | 233 (48.2) | 0.98 |